title: Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure.
abstract: OBJECTIVE
  To determine the short-term cost-utility of molecular adsorbent recirculating system (MARS) treatment in acute liver failure (ALF).
  
  
  METHODS
  A controlled retrospective study was conducted with 90 ALF patients treated with MARS from 2001 to 2005. Comparisons were made with a historical control group of 17 ALF patients treated from 2000 to 2001 in the same intensive care unit (ICU) specializing in liver diseases. The 3-year outcomes and number of liver transplantations were recorded. All direct liver disease-related medical expenses from 6 mo before to 3 years after ICU treatment were determined for 31 MARS patients and 16 control patients. The health-related quality of life (HRQoL) before MARS treatment was estimated by a panel of ICU doctors and after MARS using a mailed 15D (15-dimensional generic health-related quality of life instrument) questionnaire. The HRQoL, cost, and survival data were combined and the incremental cost/quality-adjusted life years (QALYs) was calculated.
  
  
  RESULTS
  In surviving ALF patients, the health-related quality of life after treatment was generally high and comparable to the age- and gender-matched general Finnish population. Compared to the controls, the average cost per QALY was considerably lower in the MARS group (64,732 euros vs 133,858 euros) within a timeframe of 3.5 years. The incremental cost of standard medical treatment alone compared to MARS was 10,928 euros, and the incremental number of QALYs gained by MARS was 0.66.
  
  
  CONCLUSIONS
  MARS treatment combined with standard medical treatment for ALF in an ICU setting is more cost-effective than standard medical treatment alone.
authors.affiliation: Department of Anesthesiology and Intensive Care Medicine, Surgical Hospital of Helsinki, Helsinki University Hospital, Kasarminkatu 11-13, PO Box 263, FIN-0029 HUCH, Helsinki, Finland. taru.kantola@hus.fi
authors.forename: Taru
authors.initials: T
authors.lastname: Kantola
authors.forename: Suvi
authors.initials: S
authors.lastname: Mäklin
authors.forename: Anna-Maria
authors.initials: AM
authors.lastname: Koivusalo
authors.forename: Pirjo
authors.initials: P
authors.lastname: Räsänen
authors.forename: Anne
authors.initials: A
authors.lastname: Rissanen
authors.forename: Risto
authors.initials: R
authors.lastname: Roine
authors.forename: Harri
authors.initials: H
authors.lastname: Sintonen
authors.forename: Krister
authors.initials: K
authors.lastname: Höckerstedt
authors.forename: Helena
authors.initials: H
authors.lastname: Isoniemi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D017114:Liver Failure, Acute / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D012189:Retrospective Studies; D016060:Sorption Detoxification / Q000191:economics* / Q000379:methods; D055815:Young Adult
references.citation: Curr Gastroenterol Rep. 2007 Mar;9(1):66-73
references.pmid: 17335680
references.citation: Med Care. 1989 Mar;27(3 Suppl):S91-8
references.pmid: 2921889
references.citation: Crit Care Med. 2006 Nov;34(11):2738-47
references.pmid: 16957636
references.citation: J Hepatol. 2008 Apr;48(4):567-77
references.pmid: 18279999
references.citation: Cost Eff Resour Alloc. 2006 Oct 05;4:16
references.pmid: 17022815
references.citation: Transpl Int. 2005 Jan;17(11):717-23
references.pmid: 15580335
references.citation: Liver Int. 2003;23 Suppl 3:61-5
references.pmid: 12950963
references.citation: Aliment Pharmacol Ther. 2007 Sep 1;26(5):717-26
references.pmid: 17697205
references.citation: Transplant Proc. 2008 Jul-Aug;40(6):1925-8
references.pmid: 18675091
references.citation: Ann Med. 2001 Jul;33(5):328-36
references.pmid: 11491191
references.citation: Int J Technol Assess Health Care. 2006 Spring;22(2):235-41
references.pmid: 16571199
references.citation: Metab Brain Dis. 2008 Dec;23(4):387-98
references.pmid: 18773287
references.citation: World J Gastroenterol. 2009 Jun 28;15(24):3015-24
references.pmid: 19554655
references.citation: Liver Transpl. 2009 Jan;15(1):64-72
references.pmid: 19109833
references.citation: Dig Dis Sci. 2006 Jan;51(1):47-53
references.pmid: 16416211
references.citation: Ann Med. 2001 Jul;33(5):358-70
references.pmid: 11491195
references.citation: ASAIO J. 2004 Jul-Aug;50(4):332-7
references.pmid: 15307543
references.citation: Qual Life Res. 2008 Apr;17(3):485-95
references.pmid: 18288590
references.citation: Liver. 2002;22 Suppl 2:26-9
references.pmid: 12220299
references.citation: Ann Intern Med. 2002 Dec 17;137(12):947-54
references.pmid: 12484709
references.citation: Liver Int. 2003;23 Suppl 3:66-72
references.pmid: 12950964
references.citation: Transpl Int. 2008 Sep;21(9):857-66
references.pmid: 18510596
references.citation: Artif Organs. 1993 Sep;17(9):809-13
references.pmid: 8240075
references.citation: Liver Transpl. 2000 May;6(3):277-86
references.pmid: 10827226
references.citation: ASAIO J. 1993 Jul-Sep;39(3):M621-5
references.pmid: 8268613
references.citation: Qual Life Res. 1999;8(1-2):45-54
references.pmid: 10457737
references.citation: Hepatology. 2002 Oct;36(4 Pt 1):949-58
references.pmid: 12297843